Using nanomedicine to prevent inflammation-related preterm birth.
Nanomedicine-based approach for characterizing the epigenome in prevention of inflammation-induced preterm birth.
This study is exploring a new way to help prevent early births by using tiny medicine particles to deliver treatments directly where they're needed, and it's aimed at helping women who are at risk of having preterm babies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10986100 on NIH RePORTER |
What this research studies
This research investigates a novel approach to prevent preterm birth by utilizing nanomedicine to deliver therapeutics directly to the reproductive tract. The study focuses on understanding the epigenome's role in inflammation-induced preterm birth and employs a mouse model to test the effectiveness of histone deacetylase inhibitors. By enhancing the delivery of these therapeutics, the research aims to improve pregnancy outcomes and fetal development. Patients may benefit from insights gained that could lead to new treatments for at-risk women.
Who could benefit from this research
Good fit: Ideal candidates for this research are pregnant women at high risk for preterm birth due to inflammation.
Not a fit: Patients who are not pregnant or those with no risk factors for preterm birth may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that significantly reduce the incidence of preterm births and improve outcomes for newborns.
How similar studies have performed: While the approach is innovative, similar research has shown promise in using targeted therapies to address complications in pregnancy, indicating potential for success.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Ensign, Laura — Johns Hopkins University
- Study coordinator: Ensign, Laura
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.